CN113597316A - 脂性药物制剂及其应用 - Google Patents
脂性药物制剂及其应用 Download PDFInfo
- Publication number
- CN113597316A CN113597316A CN202080021973.7A CN202080021973A CN113597316A CN 113597316 A CN113597316 A CN 113597316A CN 202080021973 A CN202080021973 A CN 202080021973A CN 113597316 A CN113597316 A CN 113597316A
- Authority
- CN
- China
- Prior art keywords
- lipid
- pharmaceutical preparation
- preparation
- lipid pharmaceutical
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 392
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 214
- 238000002360 preparation method Methods 0.000 claims abstract description 114
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims abstract description 112
- 229960004194 lidocaine Drugs 0.000 claims abstract description 107
- 239000003814 drug Substances 0.000 claims abstract description 93
- 229940079593 drug Drugs 0.000 claims abstract description 58
- 230000000202 analgesic effect Effects 0.000 claims abstract description 41
- 239000003589 local anesthetic agent Substances 0.000 claims abstract description 30
- 239000000126 substance Substances 0.000 claims abstract description 30
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960002372 tetracaine Drugs 0.000 claims abstract description 9
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960003150 bupivacaine Drugs 0.000 claims abstract description 8
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960001747 cinchocaine Drugs 0.000 claims abstract description 6
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960004288 levobupivacaine Drugs 0.000 claims abstract description 4
- LEBVLXFERQHONN-INIZCTEOSA-N levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 claims abstract description 4
- 229960001807 prilocaine Drugs 0.000 claims abstract description 4
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims abstract description 4
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 claims abstract description 3
- QTGIAADRBBLJGA-UHFFFAOYSA-N Articaine Chemical compound CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC QTGIAADRBBLJGA-UHFFFAOYSA-N 0.000 claims abstract description 3
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229960003831 articaine Drugs 0.000 claims abstract description 3
- 229960005274 benzocaine Drugs 0.000 claims abstract description 3
- 229960003976 etidocaine Drugs 0.000 claims abstract description 3
- 229960002409 mepivacaine Drugs 0.000 claims abstract description 3
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229960004919 procaine Drugs 0.000 claims abstract description 3
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229960001549 ropivacaine Drugs 0.000 claims abstract description 3
- 229940072040 tricaine Drugs 0.000 claims abstract description 3
- FQZJYWMRQDKBQN-UHFFFAOYSA-N tricaine methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=CC([NH3+])=C1 FQZJYWMRQDKBQN-UHFFFAOYSA-N 0.000 claims abstract description 3
- 208000002193 Pain Diseases 0.000 claims description 119
- 230000036407 pain Effects 0.000 claims description 119
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 81
- 239000008158 vegetable oil Substances 0.000 claims description 81
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 76
- 239000000787 lecithin Substances 0.000 claims description 76
- 235000010445 lecithin Nutrition 0.000 claims description 76
- 229940067606 lecithin Drugs 0.000 claims description 76
- 235000012424 soybean oil Nutrition 0.000 claims description 56
- 239000003549 soybean oil Substances 0.000 claims description 56
- 150000003904 phospholipids Chemical class 0.000 claims description 51
- 239000008194 pharmaceutical composition Substances 0.000 claims description 45
- 239000013583 drug formulation Substances 0.000 claims description 41
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 39
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 38
- 229960003260 chlorhexidine Drugs 0.000 claims description 38
- 238000001356 surgical procedure Methods 0.000 claims description 38
- 238000002844 melting Methods 0.000 claims description 33
- 230000008018 melting Effects 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 30
- 239000000463 material Substances 0.000 claims description 29
- 206010052428 Wound Diseases 0.000 claims description 28
- 208000027418 Wounds and injury Diseases 0.000 claims description 28
- 230000036592 analgesia Effects 0.000 claims description 22
- 230000002980 postoperative effect Effects 0.000 claims description 22
- 239000006174 pH buffer Substances 0.000 claims description 19
- 208000002847 Surgical Wound Diseases 0.000 claims description 18
- 230000003385 bacteriostatic effect Effects 0.000 claims description 16
- 235000019737 Animal fat Nutrition 0.000 claims description 14
- 235000011187 glycerol Nutrition 0.000 claims description 14
- 235000019871 vegetable fat Nutrition 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 12
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 10
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 10
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 10
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 10
- 229920001661 Chitosan Polymers 0.000 claims description 9
- 230000037396 body weight Effects 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 8
- 229920002101 Chitin Polymers 0.000 claims description 8
- 229920002674 hyaluronan Polymers 0.000 claims description 8
- 229960003160 hyaluronic acid Drugs 0.000 claims description 8
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 7
- 239000008347 soybean phospholipid Substances 0.000 claims description 7
- 235000020238 sunflower seed Nutrition 0.000 claims description 7
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 229940088710 antibiotic agent Drugs 0.000 claims description 6
- 210000001124 body fluid Anatomy 0.000 claims description 6
- 239000010839 body fluid Substances 0.000 claims description 6
- 235000012000 cholesterol Nutrition 0.000 claims description 6
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 6
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 6
- 229940124530 sulfonamide Drugs 0.000 claims description 6
- 150000003456 sulfonamides Chemical class 0.000 claims description 6
- 238000013268 sustained release Methods 0.000 claims description 6
- 239000012730 sustained-release form Substances 0.000 claims description 6
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 5
- 230000003628 erosive effect Effects 0.000 claims description 5
- 235000010413 sodium alginate Nutrition 0.000 claims description 5
- 239000000661 sodium alginate Substances 0.000 claims description 5
- 229940005550 sodium alginate Drugs 0.000 claims description 5
- 229910021538 borax Inorganic materials 0.000 claims description 4
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 claims description 4
- 235000019197 fats Nutrition 0.000 claims description 4
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 4
- 239000004328 sodium tetraborate Substances 0.000 claims description 4
- 239000007983 Tris buffer Substances 0.000 claims description 2
- 230000036765 blood level Effects 0.000 claims description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 2
- 208000001294 Nociceptive Pain Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 238000001804 debridement Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960005015 local anesthetics Drugs 0.000 abstract description 6
- 210000001519 tissue Anatomy 0.000 description 45
- 230000000694 effects Effects 0.000 description 21
- 239000000203 mixture Substances 0.000 description 18
- 229960005150 glycerol Drugs 0.000 description 12
- 238000009472 formulation Methods 0.000 description 9
- 230000007774 longterm Effects 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 7
- 229940035676 analgesics Drugs 0.000 description 6
- 239000000730 antalgic agent Substances 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 235000011837 pasties Nutrition 0.000 description 6
- 229940042577 exparel Drugs 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 159000000000 sodium salts Chemical class 0.000 description 5
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 4
- 238000012084 abdominal surgery Methods 0.000 description 4
- 230000003444 anaesthetic effect Effects 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 210000000436 anus Anatomy 0.000 description 4
- 210000003195 fascia Anatomy 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- -1 lecithin) Chemical class 0.000 description 3
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 3
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 3
- 229940060977 lidoderm Drugs 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 229940036950 pliaglis Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 229940019097 EMLA Drugs 0.000 description 2
- 241001562081 Ikeda Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- WZSPWMATVLBWRS-UHFFFAOYSA-N 2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide;n-(2-methylphenyl)-2-(propylamino)propanamide Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C.CCN(CC)CC(=O)NC1=C(C)C=CC=C1C WZSPWMATVLBWRS-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010053692 Wound complication Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 208000005135 methemoglobinemia Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008337 systemic blood flow Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Anesthesiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
一种脂性药物制剂及其应用。该脂性药物制剂包括局部麻醉药和脂类物质,局部麻醉药在脂性药物制剂中的质量百分比为2%‑50%,局部麻醉药为利多卡因、丁卡因、布比卡因、阿替卡因、辛可卡因、地布卡因、依替卡因、左布比卡因、甲哌卡因、丙胺卡因、罗哌卡因、三甲卡因、苯佐卡因或普鲁卡因;脂类物质在脂性药物制剂中的质量百分比为30%‑98%;所述脂性药物制剂中各组分的质量百分比之和为100%。在许多镇痛应用中,该脂性药物制剂,能够获得12、24、36、48、72小时,甚至更长时间的连续安全镇痛效果。
Description
PCT国内申请,说明书已公开。
Claims (20)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910299949.9A CN111840553A (zh) | 2019-04-15 | 2019-04-15 | 脂性药物制剂及其应用 |
CN2019102999499 | 2019-04-15 | ||
PCT/CN2020/084832 WO2020211762A1 (zh) | 2019-04-15 | 2020-04-15 | 脂性药物制剂及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113597316A true CN113597316A (zh) | 2021-11-02 |
CN113597316B CN113597316B (zh) | 2023-11-24 |
Family
ID=72838033
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910299949.9A Pending CN111840553A (zh) | 2019-04-15 | 2019-04-15 | 脂性药物制剂及其应用 |
CN202080021973.7A Active CN113597316B (zh) | 2019-04-15 | 2020-04-15 | 脂性药物制剂及其应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910299949.9A Pending CN111840553A (zh) | 2019-04-15 | 2019-04-15 | 脂性药物制剂及其应用 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20220193014A1 (zh) |
EP (1) | EP3957328A4 (zh) |
CN (2) | CN111840553A (zh) |
WO (1) | WO2020211762A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111840553A (zh) * | 2019-04-15 | 2020-10-30 | 湖州依诺唯新药物制剂有限公司 | 脂性药物制剂及其应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115252557B (zh) * | 2022-09-01 | 2023-06-02 | 广东嘉博制药有限公司 | 一种罗哌卡因多囊脂质体制剂的制备方法 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0770387A1 (en) * | 1995-10-28 | 1997-05-02 | B. Braun Melsungen Ag | Pharmaceutical composition containing a local anesthetic and/or centrally acting analgesic |
WO2001019403A1 (en) * | 1999-09-14 | 2001-03-22 | Lim Jung Ok | Liposomal mixture of local anesthetics and manufacturing method thereof |
US20050287180A1 (en) * | 2004-06-15 | 2005-12-29 | Chen Andrew X | Phospholipid compositions and methods for their preparation and use |
CN101904814A (zh) * | 2009-06-04 | 2010-12-08 | 上海恒瑞医药有限公司 | 制备载药乳剂的方法 |
US20110015229A1 (en) * | 2009-01-06 | 2011-01-20 | Jie Zhang | Method of treating neuropathic pain |
CN102370619A (zh) * | 2010-08-18 | 2012-03-14 | 罗和国 | 脂肪乳乳化局麻药 |
AR082287A1 (es) * | 2011-07-19 | 2012-11-28 | Zars Pharma Inc | Una formulacion anestesica local formadora de solido |
CN102933200A (zh) * | 2009-12-18 | 2013-02-13 | 莱迪杜德制药公司 | 包含磷脂的单相凝胶组合物 |
CN108159055A (zh) * | 2018-01-04 | 2018-06-15 | 西安力邦医药科技有限责任公司 | 治疗乳腺癌的长效递药系统、其制备方法及应用 |
CN108743952A (zh) * | 2018-06-11 | 2018-11-06 | 西安力邦医药科技有限责任公司 | 局部麻醉药的磷脂-混溶剂-油缓释递药系统组方与制备方法 |
CN109316602A (zh) * | 2018-11-13 | 2019-02-12 | 西安力邦医药科技有限责任公司 | 一种长效镇痛并促进伤口愈合的复方缓释递药系统的组方与应用 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0647533B2 (ja) * | 1984-08-10 | 1994-06-22 | 裕 水島 | 4−ビフエニリル酢酸系化合物含有脂肪乳剤 |
US5227165A (en) * | 1989-11-13 | 1993-07-13 | Nova Pharmaceutical Corporation | Liposphere delivery systems for local anesthetics |
SE9200762D0 (sv) * | 1992-03-12 | 1992-03-12 | Astra Ab | New topical use |
SE9402453D0 (sv) * | 1994-07-12 | 1994-07-12 | Astra Ab | New pharmaceutical preparation |
AU2003225745A1 (en) * | 2002-03-12 | 2003-09-29 | Neurogesx, Inc. | Free-base formulations of local anesthetics |
US20060127429A1 (en) * | 2004-12-13 | 2006-06-15 | Mccartt Mary D | Topical numbing composition for laser therapy |
US20080207560A1 (en) * | 2005-01-07 | 2008-08-28 | Ayako Harada | Composition For External Use |
US9918934B2 (en) * | 2006-12-12 | 2018-03-20 | Edgar Joel Acosta-Zara | Linker-based lecithin microemulsion delivery vehicles |
US20140066481A1 (en) * | 2010-04-01 | 2014-03-06 | Pharmanest Ab | Water-Free Pharmaceutical Compositions Suitable for Local Anaesthetics |
EP2552487B1 (en) * | 2010-04-01 | 2016-10-19 | Pharmanest AB | Thermogelling anaesthetic compositions |
CN103705439B (zh) * | 2012-09-28 | 2017-11-28 | 上海恒瑞医药有限公司 | 脂质凝胶药物制剂及其制备方法和用途 |
CN103705442B (zh) * | 2012-09-28 | 2017-12-01 | 上海恒瑞医药有限公司 | 原位脂质凝胶药物制剂及其制备方法和用途 |
CN103142458B (zh) * | 2013-01-22 | 2015-09-09 | 莱普德制药有限公司 | 无成瘾性镇痛缓释递药系统的组方与制备方法 |
CN106943340A (zh) * | 2017-04-28 | 2017-07-14 | 北京茗泽中和药物研究有限公司 | 一种盐酸利多卡因凝胶 |
CN108354903A (zh) * | 2018-04-11 | 2018-08-03 | 西安力邦生物医药技术有限公司 | 一种局部麻醉镇痛缓释递药系统及其制备方法和应用 |
CN108379269B (zh) * | 2018-04-20 | 2020-08-21 | 武汉百纳礼康生物制药有限公司 | 一种用于术后镇痛的缓释制剂及其制备方法 |
CN111840553A (zh) * | 2019-04-15 | 2020-10-30 | 湖州依诺唯新药物制剂有限公司 | 脂性药物制剂及其应用 |
-
2019
- 2019-04-15 CN CN201910299949.9A patent/CN111840553A/zh active Pending
-
2020
- 2020-04-15 EP EP20792218.8A patent/EP3957328A4/en not_active Withdrawn
- 2020-04-15 US US17/603,015 patent/US20220193014A1/en active Pending
- 2020-04-15 CN CN202080021973.7A patent/CN113597316B/zh active Active
- 2020-04-15 WO PCT/CN2020/084832 patent/WO2020211762A1/zh unknown
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0770387A1 (en) * | 1995-10-28 | 1997-05-02 | B. Braun Melsungen Ag | Pharmaceutical composition containing a local anesthetic and/or centrally acting analgesic |
WO2001019403A1 (en) * | 1999-09-14 | 2001-03-22 | Lim Jung Ok | Liposomal mixture of local anesthetics and manufacturing method thereof |
US20050287180A1 (en) * | 2004-06-15 | 2005-12-29 | Chen Andrew X | Phospholipid compositions and methods for their preparation and use |
US20110015229A1 (en) * | 2009-01-06 | 2011-01-20 | Jie Zhang | Method of treating neuropathic pain |
CN101904814A (zh) * | 2009-06-04 | 2010-12-08 | 上海恒瑞医药有限公司 | 制备载药乳剂的方法 |
CN102933200A (zh) * | 2009-12-18 | 2013-02-13 | 莱迪杜德制药公司 | 包含磷脂的单相凝胶组合物 |
CN102370619A (zh) * | 2010-08-18 | 2012-03-14 | 罗和国 | 脂肪乳乳化局麻药 |
AR082287A1 (es) * | 2011-07-19 | 2012-11-28 | Zars Pharma Inc | Una formulacion anestesica local formadora de solido |
CN108159055A (zh) * | 2018-01-04 | 2018-06-15 | 西安力邦医药科技有限责任公司 | 治疗乳腺癌的长效递药系统、其制备方法及应用 |
CN108743952A (zh) * | 2018-06-11 | 2018-11-06 | 西安力邦医药科技有限责任公司 | 局部麻醉药的磷脂-混溶剂-油缓释递药系统组方与制备方法 |
CN109316602A (zh) * | 2018-11-13 | 2019-02-12 | 西安力邦医药科技有限责任公司 | 一种长效镇痛并促进伤口愈合的复方缓释递药系统的组方与应用 |
Non-Patent Citations (1)
Title |
---|
RITTES, JC等: "Comparative evaluation of propofol in nanoemulsion with solutol and soy lecithin for general anesthesia", REVISTA BRASILEIRA DE ANESTESIOLOGIA, vol. 66, no. 3, pages 225 - 230 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111840553A (zh) * | 2019-04-15 | 2020-10-30 | 湖州依诺唯新药物制剂有限公司 | 脂性药物制剂及其应用 |
Also Published As
Publication number | Publication date |
---|---|
EP3957328A4 (en) | 2023-03-22 |
CN113597316B (zh) | 2023-11-24 |
CN111840553A (zh) | 2020-10-30 |
EP3957328A1 (en) | 2022-02-23 |
US20220193014A1 (en) | 2022-06-23 |
WO2020211762A1 (zh) | 2020-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103142458B (zh) | 无成瘾性镇痛缓释递药系统的组方与制备方法 | |
CN108743952B (zh) | 局部麻醉药的磷脂-混溶剂-油缓释递药系统组方与制备方法 | |
US9511016B2 (en) | Topical composition for treating pain | |
EP1809329B1 (en) | Sustained local anesthetic composition containing saib | |
KR101792200B1 (ko) | 열감응성 겔 마취제 조성물 | |
US9427416B2 (en) | Composition and method for treating hemorrhoids and/or anorectal disorders | |
CN105120839B (zh) | 可注射长效局麻药半固体制剂及其组成成分 | |
CN113597316B (zh) | 脂性药物制剂及其应用 | |
KR20200119351A (ko) | 수계 캡사이시노이드 제형 및 제조 방법 및 용도 | |
AU2006269195A1 (en) | Synergistic time-delaying agent for local anestheic | |
WO2014016647A1 (en) | PHARMACEUTICAL COMPOSITION OF MILK FAT GLOBULES (MFGs) ZINC FREE | |
WO2018147790A1 (en) | Anaesthetic composition comprising ropivacaine, prilocaine and lidocaine | |
JP2002322071A (ja) | 蜂針を用いない蜂毒療法 | |
EP1884241B1 (en) | A oral preparation comprising dyclonine hydrochloride | |
EP3525767A1 (en) | Topical formulations and treatments | |
WO2021257027A1 (en) | An effective composition in healing wounds | |
WO2008113421A1 (de) | Neue pharmazeutische zusammensetzungen für die lipolyse und verfahren zu deren herstellung | |
US20230000772A1 (en) | Opioid independent surgical anesthetic | |
EP4052697A1 (en) | Opioid independent surgical anesthetic | |
RU2286781C2 (ru) | Способ лечения химических ожогов пищевода у детей | |
RU2817847C1 (ru) | Суппозиторий для лечения ректальных трещин гиалуроновый с димексидом | |
JP7450916B2 (ja) | 表面麻酔剤 | |
US20210015965A1 (en) | Means and methods for wound healing | |
KR20000017706A (ko) | 국소마취제를함유한약용겔제조성물 | |
WO2023217384A1 (en) | Pharmaceutical composition for topical administration comprising a volatile anaesthetic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |